Paid is not covered: build the access case around the policy, not the claims

The number that tempts, and the clause that matters

The headline in Lucid Diagnostics' latest update is easy to like. Medicare is paying EsoGuard claims at the full fee schedule rate of $1,938.01 per test, and the company reports record October volume. PAVmed's preliminary Q3 update confirms Lucid has been paid by Medicare since October.

The clause that matters is further down. Coverage is being granted case by case, while a wider MolDX reconsideration remains pending. A reimbursement rate is not a coverage policy. Case-by-case payment means individual claims are succeeding. It does not tell us that every eligible patient, site or payer contractor can count on the same outcome next quarter.

My position: market access teams should treat this kind of payment as evidence of traction and as a risk to be modelled, never as the base case. Plan on the policy, not the claims.

What we do not know

The records do not say how many claims have been paid, on what basis individual cases are being approved, or when the reconsideration will conclude. They do not say what outcome it might reach. Without those facts, any forecast that extrapolates October volume into a durable run-rate is guesswork presented as a plan.

Case-by-case determinations tend to be shaped by documentation. If payment depends on what accompanies each claim, then the quality of that file is part of the product. That is a general point about how individual coverage decisions work, not a finding about this company. The records are silent on the mechanics, so teams in similar positions should find out what actually drives approvals rather than assume.

The strongest counter-argument

The best objection is that real money at the full rate beats a hypothetical policy. A payer that pays at the full fee schedule rate has accepted the price. Paid claims build a track record, and a reconsideration is easier to win when the product is already being reimbursed. Waiting for a tidy policy before engaging would be its own kind of failure.

That is fair, and nobody should ignore the payments. But the argument cuts both ways. A track record helps only if it is documented and organised for the reviewer, and a favourable reconsideration is a hope until it is issued. The right response to paid claims is to use them as evidence, not to treat them as a substitute for a decision.

The pipeline lesson

PAVmed's update also describes Veris Health freezing its monitor design and starting an animal study ahead of an early-2027 FDA 510(k) submission. A 510(k) is a premarket notification showing a device is substantially equivalent to a legally marketed one. It is a regulatory gate, not a payment decision. The records give no view on how Veris would be reimbursed.

That gap is the point. Device and diagnostic teams routinely finish the regulatory work first and discover the coverage question afterwards. The EsoGuard story shows how long and uneven that second road can be: a product with a reported payment rate still sits under a pending coverage reconsideration. Evidence generation for payers should be designed alongside the regulatory file, not after it.

Recommendation

Run two forecasts. One assumes the reconsideration widens coverage. The other assumes case-by-case coverage persists or narrows. Make every commercial and resourcing decision survive the second. Meanwhile, convert each approved claim into usable evidence: what was submitted, what was accepted, and where claims failed. Then be ready to put that record in front of the reviewer when the reconsideration moves.